Crinetics Pharmaceuticals (CRNX) has had the highest return since June 3, 2026 by a mid-cap US stock, returning 156.7%.
| ASSET | % RETURN |
|---|---|
Crinetics Pharmaceuticals (CRNX) | 156.7% |
Definium Therapeutics (DFTX) | 106.9% |
MBX Biosciences, Inc Common Stock (MBX) | 99.97% |
Kymera Therapeutics (KYMR) | 68.15% |
Newell Brands (NWL) | 59.08% |
Uniqure (QURE) | 57.77% |
Sellas Life Sciences (SLS) | 57.14% |
Oruka Therapeutics (ORKA) | 56.58% |
Biohaven (BHVN) | 56.12% |
Agios Pharm (AGIO) | 55.53% |
Sezzle (SEZL) | 54.91% |
Ultragenyx (RARE) | 54.78% |
Dave (DAVE) | 52.92% |
Hinge Health (HNGE) | 51.95% |
Kardigan, Inc Common Stock (KARD) | 51.6% |
TG Therapeutics (TGTX) | 48.09% |
ELF Beauty (ELF) | 47.54% |
Enova International (ENVA) | 47.53% |
Oscar Health (OSCR) | 45.57% |
Tango Therapeutics (TNGX) | 45.48% |
Enliven Therapeutics (ELVN) | 44.32% |
Structure Therapeutics Inc American Depositary Shares (GPCR) | 42.67% |
Pattern Group Inc Series A Common Stock (PTRN) | 42.54% |
Aveanna Healthcare (AVAH) | 42.44% |
Nurix Therapeutics (NRIX) | 41.39% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.